Status:
COMPLETED
XIENCE V® EXCEED: Evaluation of XIENCE V® Catheterization Lab Endpoints and Excellence in Delivery
Lead Sponsor:
Abbott Medical Devices
Conditions:
Atherosclerosis
Coronary Artery Disease
Eligibility:
All Genders
Brief Summary
This trial is to assess physician-determined XIENCE V® EECSS acute performance, deliverability and resource utilization in the catheterization lab during commercial use by various physicians with a ra...
Detailed Description
This study will evaluate overall physician-determined XIENCE V® Everolimus Eluting Coronary Stent system (XIENCE V®) acute performance, deliverability and resource utilization in the catheterization l...
Eligibility Criteria
Inclusion
- General
- The patient agrees to participate in this study by signing the IRB approved informed consent form prior to the index procedure.
- Alternatively, the patient's legally authorized representative agrees to the patient's participation in this study and signs the informed consent form prior to the index procedure.
- General
Exclusion
- Inability to obtain an informed consent is an exclusion criterion.
Key Trial Info
Start Date :
October 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2009
Estimated Enrollment :
2517 Patients enrolled
Trial Details
Trial ID
NCT00731237
Start Date
October 1 2008
End Date
October 1 2009
Last Update
October 16 2009
Active Locations (44)
Enter a location and click search to find clinical trials sorted by distance.
1
The Heart Center, PC
Huntsville, Alabama, United States, 35801
2
Arizona Regional Medical Center
Mesa, Arizona, United States, 85206
3
Tri Lakes Research-Central Arkansas Cardiovascular
Hot Springs, Arkansas, United States, 71913
4
Tri Lakes Research-Central Arkansas Cardiovascular
Hot Springs Village, Arkansas, United States, 71909